REGENXBIO on Why It’s Better Here

For Curran Simpson, Chief Operations and Technology Officer at REGENXBIO, Maryland has the “ideal mix” of talent for process development and manufacturing. Because if that, it was a no-brainer for the company to opening of its new Manufacturing Innovation Center gene therapy manufacturing facility in Rockville.

The new 132,000 square-foot-facility was designed to boost manufacturing of the company’s NAV Technology-based adeno-associated virus (AAV) vectors at scales up to 2,000 liters. REGENXBIO’s AAV vector platform has been licensed to other companies and was used in the development of Novartis’ Zolgensma, a gene therapy for spinal muscular atrophy. With its new site that includes two independent bulk drug substance production suites, a final drug product suite and integrated quality control labs, REGENXBIO is one of only a few gene therapy companies worldwide with a GMP facility capable of production at scales up to 2,000 liters.

Read the full article via the Maryland Tech Council’s “It’s Better Here” newsletter at: